In November 2023, pharmaceutical manufacturer PaxMedica announced the successful completion of a Phase 2 clinical trial of suramin for children with autism. The research was published in the medical journal Annals of General Psychiatry.

A randomized controlled trial involving 52 boys with moderate to severe autism between the ages of 4 and 15 found that treatment with low-dose intravenous suramin was It helped children who received the drug develop better than children in the placebo group.

More research is needed.

Mark Cavitt, director of the Child Psychiatry Center at Johns Hopkins All Children's Hospital, commented: In the preliminary experiment Suramin shows effectiveness in treating autism. But results from Phase 2 and 3 clinical trials with larger samples of hundreds of patients need to be confirmed. In order to get sufficient information that Suramin can be used as an effective and safe treatment for autism.

thefreelibrary.com